中金发表报告指出，石四药(02005.HK) 去年收入按年跌10.7%至57.73亿港元，净利润跌19.5%至10.61亿元，逊该行预期，主要由于受集中采购的影响，安瓿注射剂产品的收入降幅超过预期。
由于石四药部分产品价格受到集中采购的影响，该行将其今明两年年净利润预测下调14.8%及11.4%，至11.74亿与13.44亿港元。该行维持对其“跑赢行业”评级，目标价降5.3%至4.26港元。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-03 16:25。)
中金发表报告指出，石四药(02005.HK) 去年收入按年跌10.7%至57.73亿港元，净利润跌19.5%至10.61亿元，逊该行预期，主要由于受集中采购的影响，安瓿注射剂产品的收入降幅超过预期。
由于石四药部分产品价格受到集中采购的影响，该行将其今明两年年净利润预测下调14.8%及11.4%，至11.74亿与13.44亿港元。该行维持对其“跑赢行业”评级，目标价降5.3%至4.26港元。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-03 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.